-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Professor Susan Treves remembers seeing a 6-month-old child with the disease
The affected genes contain the blueprint for a calcium channel called RYR1 in skeletal muscle
genetic material overload
This therapy is based on the observation that certain enzymes are overproduced in the patient's skeletal muscle
Treves and her team used inhibitors of these enzymes, already approved as cancer drugs or in clinical trials
From gene to therapy
This approach is still a long way from a clinically applicable treatment, Treves said
For Susan Treves and Francesco Zorzato, these first promising results represent a landmark victory after more than 10 years of research -- especially since Zorzato was the first to isolate a gene that affects these muscle diseases a few years ago people
Journal Reference :
Alexis Ruiz, Sofia Benucci, Urs Duthaler, Christoph Bachmann, Martina Franchini, Faiza Noreen, Laura Pietrangelo, Feliciano Protasi, Susan Treves, Francesco Zorzato.